Search
Skye Bioscience Inc
SKYEAdd to Watchlist
0.569USD
-0.012-2.03%
Close 07-31 16:00（ET）Quotes delayed by 15 min
19.98MMarket Cap
LossP/E TTM
More Details of Skye Bioscience Inc Company
Skye Bioscience, Inc. is a clinical-stage biotechnology company. The Company is focused on development of next-generation molecules that modulate G-protein coupled receptors to treat obesity, overweight, and related conditions. The Company’s lead candidate, nimacimab, is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1). The Company is also focused on its Phase IIa clinical trial, CBeyond, for nimacimab. The CBeyond clinical trial includes approximately 136 patients, 16 clinical trial sites and a combination arm with a GLP-1 receptor agonist to assess differences in weight loss, body composition, and other attributes. The CB1 receptor is one of the receptors in the endocannabinoid system (ECS) and plays a significant role both in the central nervous system (CNS) and peripheral tissues. The Company's Phase II study in obesity for nimacimab, is a negative allosteric modulating antibody that peripherally inhibits CB1.
Skye Bioscience Inc Info
Ticker SymbolSKYE
Company nameSkye Bioscience Inc
IPO dateFeb 24, 2014
CEODhillon (Punit S)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 24
Address11250 El Camino Real, Suite 100
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18584100266
Websitehttps://skyebioscience.com/
Ticker SymbolSKYE
IPO dateFeb 24, 2014
CEODhillon (Punit S)
Company Executives of Skye Bioscience Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Punit S. Dhillon
Dr. Punit S. Dhillon
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
173.12K
+1.62%
Mr. Christopher (Chris) Twitty, Ph.D.
Mr. Christopher (Chris) Twitty, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
81.24K
--
Mr. Tuan Tu Diep
Mr. Tuan Tu Diep
Chief Operating Officer
Chief Operating Officer
41.85K
+6.69%
Ms. Kaitlyn Arsenault, CPA
Ms. Kaitlyn Arsenault, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Deborah Charych, Ph.D.
Dr. Deborah Charych, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew J. (Andy) Schwab
Mr. Andrew J. (Andy) Schwab
Director
Director
--
--
Mr. Paul A. Grayson
Mr. Paul A. Grayson
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Annalisa M. Jenkins
Dr. Annalisa M. Jenkins
Independent Director
Independent Director
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Puneet S. Arora
Dr. Puneet S. Arora
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Punit S. Dhillon
Dr. Punit S. Dhillon
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
173.12K
+1.62%
Mr. Christopher (Chris) Twitty, Ph.D.
Mr. Christopher (Chris) Twitty, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
81.24K
--
Mr. Tuan Tu Diep
Mr. Tuan Tu Diep
Chief Operating Officer
Chief Operating Officer
41.85K
+6.69%
Ms. Kaitlyn Arsenault, CPA
Ms. Kaitlyn Arsenault, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Deborah Charych, Ph.D.
Dr. Deborah Charych, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andrew J. (Andy) Schwab
Mr. Andrew J. (Andy) Schwab
Director
Director
--
--
FAQs
Who are the top five shareholders of Skye Bioscience Inc?
The top five shareholders of Skye Bioscience Inc are: Dr. Punit S. Dhillon
How many institutions hold shares of Skye Bioscience Inc (SKYE)?
As of 2026Q1, 173 institutions hold shares of Skye Bioscience Inc, with a combined market value of approximately 17.02M, accounting for 48.44% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -9941102.00.